Angiodynamics (ANGO) Amortization of Deferred Charges (2026)

Angiodynamics (ANGO) posted Amortization of Deferred Charges of $73000.0 for Q2 2026, up 1.39% on a QoQ basis from $72000.0 in Q1 2026.

Angiodynamics (ANGO) Amortization of Deferred Charges (2026) Analysis & Trends

Angiodynamics' Amortization of Deferred Charges history runs 1 years deep, the most recent figure standing at $73000.0 for Q2 2026.

Quarterly Amortization of Deferred Charges changed N/A year-over-year to $73000.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $145000.0 (changed N/A YoY) and the FY2026 annual result came in at $290000.0, changed N/A from the prior year.
Amortization of Deferred Charges was $73000.0 for Q2 2026 at Angiodynamics, up from $72000.0 in the prior quarter.
Across five years, Amortization of Deferred Charges topped out at $73000.0 in Q2 2026 and bottomed at $72000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alcon	32,734,969.19 Bn	32,734,967.53 Bn	1.53 Bn
2	Intuitive Surgical	117.50 Bn	112.41 Bn	1.96 Bn
3	Becton Dickinson	42.93 Bn	42.11 Bn	2.15 Bn
4	Medline	30.82 Bn	36.66 Bn	1.84 Bn
5	Resmed	27.90 Bn	26.23 Bn	890.98 Mn
6	West Pharmaceutical Services	26.76 Bn	26.23 Bn	329.20 Mn
7	Cooper Companies	15.30 Bn	15.16 Bn	735.40 Mn
8	Solventum	13.46 Bn	12.90 Bn	1.10 Bn
9	Align Technology	12.02 Bn	10.96 Bn	736.59 Mn
10	Angiodynamics	558.11 Mn	504.25 Mn	46.77 Mn

Download Data